Elevated soluble CD 27 levels (TNF-receptor) may predict survival in diffuse large B-cell lymphoma - Revisiting "the super-family " saga

Leukemia and Lymphoma

Volumn 53, Issue 8, 2012, Pages 1439-1440

  Tadmor, Tamar ^a   Polliack, Aaron ^b  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; UPREGULATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD27; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PREDNISONE; VINCRISTINE;

EID: 84864200538     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.666546     Document Type: Article

References (14)

1. , Tsurumi H, Takemura M, et al. Serum soluble CD27 level is associated with outcome in patients with diff use large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. Leuk Lymphoma 2012;53:1494-1500.
2. van Oers M, Pals S, Evers L, et al. Expression and release of CD27 in human B-cell malignancies. Blood 1993;82:3430-3436.
3. K ok M, Bonfrer JM, Korse CM, et al. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma. Tumour Biol 2003;24:53-60.
4. Murase S, Saio M, Takenaka K, et a l. Increased levels of CSF soluble CD27 in patients with primary central nervous system lymphoma. Cancer Lett 1998;132:181-186.
5. G oto N, Tsurumi H, Takemura M, et a l. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma. Eur J Haematol 2006;77:217-225.
6. Hintzen R, Lens S, Lammers K, et al. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol 1995;154:2612-2623.
7. Denoeud J, Moser M. Role of CD27/CD70 pathway of activation in immunity and tolerance. J Leukoc Biol 2011;89:195-203.
8. N olte MA, Van Olff en RW, Van Gisbergen KPJM, et a l. Timing and tuning of CD27 - CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 2009;229:216-231.
9. Dang LV, Nilsson A, Ingelman-Sundberg H, et al. Soluble CD27 induces IgG production through activation of antigen-primed B cells. J Intern Med 2011 Sep 14. [Epub ahead of print]
10. L ens SMA, Drillenburg P, Den Drijver BFA, et al. Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol 1999;106:491-503.
11. Widney D, Gundapp G, Said JW, et a l. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDSassociated lymphoma. Clin Immunol 1999;93:114-123.
12. A kbar AN, Vukmanovic-Stejic M, Taams LS, et a l. Th e dynamic co-evolution of memory and regulatory CD4- T cells in the periphery. Nat Rev Immunol 2007;7:231-237.
13. McEarchern JA, Smith LM, McDonagh CF, et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res 2008;14:7763-7772.
14. Israel BF, Gulley M, Elmore S, et al. Anti-CD70 antibodies: a potential treatment for EBV- CD70-expressing lymphomas. Mol Cancer Ther 2005;4:2037-2044.